# A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis

> **NCT07344051** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Moderate-to-severe Atopic Dermatitis

## Interventions

- **DRUG:** QLS12010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07344051
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-05
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07344051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07344051, "A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07344051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*